WEKO3
アイテム
{"_buckets": {"deposit": "22c1db27-b8ed-494c-a2d2-4face7dd43f0"}, "_deposit": {"created_by": 2, "id": "5155", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "5155"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00005155", "sets": ["30"]}, "author_link": ["21359", "21360"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2014-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "363", "bibliographicPageStart": "353", "bibliographicVolumeNumber": "15", "bibliographic_titles": [{"bibliographic_title": "Expert Opinion on Pharmacotherapy"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Introduction: The prevalence of bronchial asthma, which is a chronic inflammatory disorder of the airway, is increasing worldwide. Although inhaled corticosteroids (ICS) play a central role in the treatment of asthma, they cannot achieve good control for all asthmatics, and medications such as leukotriene receptor antagonists (LTRAs) with bronchodilatory and anti-inflammatory effects often serve as alternatives or add-on drugs. Areas covered: Clinical trials as well as basic studies of montelukast and pranlukast in animal models are ongoing. This review report clarifies the current status of these two LTRAs in the treatment of asthma and their future direction. Expert opinion: LTRAs could replace ICS as first-line medications for asthmatics who are refractory to ICS or cannot use inhalant devices. Further, LTRAs are recommended for asthmatics under specific circumstances that are closely associated with cysteinyl leukotrienes (cysLTs). Considering the low incidence of both severe adverse effects and the induction of tachyphylaxis, oral LTRAs should be more carefully considered for treating asthma in the clinical environment. Several issues such as predicted responses, effects of peripheral airway and airway remodeling and alternative administration routes remain to be clarified before LTRAs could serve a more effective role in the treatment of asthma.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Expert Opinion on Pharmacotherapy, 15(3), pp.353-363; 2014", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Informa Healthcare"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1517/14656566.2014.872241", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c 2014 Informa UK, Ltd."}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "14656566", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "17447666", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Matsuse, Hiroto"}], "nameIdentifiers": [{"nameIdentifier": "21359", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kohno, Shigeru"}], "nameIdentifiers": [{"nameIdentifier": "21360", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "EOP15_353.pdf", "filesize": [{"value": "273.8 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 273800.0, "url": {"label": "EOP15_353.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/5155/files/EOP15_353.pdf"}, "version_id": "d226a9f0-7488-4bc2-a1df-eff5720a3b04"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Airway hyperresponsiveness", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Bronchodilation", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Inflammation", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Pulmonary function", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Tachyphylaxis", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Leukotriene receptor antagonists pranlukast and montelukast for treating asthma", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Leukotriene receptor antagonists pranlukast and montelukast for treating asthma"}]}, "item_type_id": "2", "owner": "2", "path": ["30"], "permalink_uri": "http://hdl.handle.net/10069/34197", "pubdate": {"attribute_name": "公開日", "attribute_value": "2015-03-01"}, "publish_date": "2015-03-01", "publish_status": "0", "recid": "5155", "relation": {}, "relation_version_is_last": true, "title": ["Leukotriene receptor antagonists pranlukast and montelukast for treating asthma"], "weko_shared_id": -1}
Leukotriene receptor antagonists pranlukast and montelukast for treating asthma
http://hdl.handle.net/10069/34197
http://hdl.handle.net/10069/3419760dcf3a6-ac22-4468-8e67-519c8cf81be0
名前 / ファイル | ライセンス | アクション |
---|---|---|
EOP15_353.pdf (273.8 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2015-03-01 | |||||
タイトル | ||||||
タイトル | Leukotriene receptor antagonists pranlukast and montelukast for treating asthma | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Airway hyperresponsiveness | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Bronchodilation | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Inflammation | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Pulmonary function | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Tachyphylaxis | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Matsuse, Hiroto
× Matsuse, Hiroto× Kohno, Shigeru |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Introduction: The prevalence of bronchial asthma, which is a chronic inflammatory disorder of the airway, is increasing worldwide. Although inhaled corticosteroids (ICS) play a central role in the treatment of asthma, they cannot achieve good control for all asthmatics, and medications such as leukotriene receptor antagonists (LTRAs) with bronchodilatory and anti-inflammatory effects often serve as alternatives or add-on drugs. Areas covered: Clinical trials as well as basic studies of montelukast and pranlukast in animal models are ongoing. This review report clarifies the current status of these two LTRAs in the treatment of asthma and their future direction. Expert opinion: LTRAs could replace ICS as first-line medications for asthmatics who are refractory to ICS or cannot use inhalant devices. Further, LTRAs are recommended for asthmatics under specific circumstances that are closely associated with cysteinyl leukotrienes (cysLTs). Considering the low incidence of both severe adverse effects and the induction of tachyphylaxis, oral LTRAs should be more carefully considered for treating asthma in the clinical environment. Several issues such as predicted responses, effects of peripheral airway and airway remodeling and alternative administration routes remain to be clarified before LTRAs could serve a more effective role in the treatment of asthma. | |||||
書誌情報 |
Expert Opinion on Pharmacotherapy 巻 15, 号 3, p. 353-363, 発行日 2014-02 |
|||||
出版者 | ||||||
出版者 | Informa Healthcare | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 14656566 | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 17447666 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1517/14656566.2014.872241 | |||||
権利 | ||||||
権利情報 | c 2014 Informa UK, Ltd. | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Expert Opinion on Pharmacotherapy, 15(3), pp.353-363; 2014 |